Bone Mineralization and Vascularization in Bisphosphonate-related Osteonecrosis of the Jaw: an Experimental Study in the Rat

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2018 Feb 18

PMID 29453497

Citations 16

Authors

Jean-Daniel Kun-Darbois

Helene Libouban

Guillaume Mabilleau

Florence Pascaretti-Grizon

Daniel Chappard

Affiliations

Soon will be listed here.

Abstract

Objectives: Pathogenesis of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is not fully explained. An antiangiogenic effect of bisphosphonates (BPs) or an altered bone quality have been advocated. The aims of the present study were to analyze alveolar mandibular vascularization and bone quality in rats with BRONJ.

Materials And Methods: Thirty-eight Sprague-Dawley rats were randomized into two groups: zoledronic acid (ZA), n = 27, and control (CTRL) n = 11. The ZA group received a weekly IV injection of ZA (100 μg/kg) during 10 weeks. The CTRL group received saline. After 6 weeks, extraction of the right mandibular molars was performed. Rats were sacrificed after 14 weeks. Microtomography characterized bone lesions and vascularization after injection of a radio-opaque material. Raman microspectroscopy evaluated bone mineralization.

Results: Fifty-five percent of ZA rats presented bone exposure and signs of BRONJ. None sign was found at the left hemimandible in the ZA group and in the CTRL group. Vascular density appeared significantly increased in the right hemimandibles of the CTRL group compared to the left hemimandibles. Vascularization was reduced in the ZA group. A significantly increased of the mineral-to-amide ratio was found in the alveolar bone of ZA rats by Raman microspectroscopy.

Conclusions: In a rat model of BRONJ, microtomography evidenced osteonecrosis in BRONJ. Raman spectroscopy showed an increased mineralization. Vascularization after tooth extraction was impaired by ZA.

Clinical Relevance: Prolonged BP administration caused an increase in the mineralization and a quantitative reduction of the vascularization in the alveolar bone; both factors might be involved concomitantly in the BRONJ pathophysiology.

Citing Articles

Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.

Bojtor B, Balla B, Vaszilko M, Szentpeteri S, Putz Z, Kosa J Int J Mol Sci. 2024; 25(19).

PMID: 39408816 PMC: 11477157. DOI: 10.3390/ijms251910488.

Pathogenesis of Medication-Related Osteonecrosis of the Jaw: Odontogenic Infection-Preceding Type and Osteonecrosis-Preceding Type.

Sakamoto Y, Sawada S, Kojima Y Cureus. 2024; 16(5):e60223.

PMID: 38868238 PMC: 11167574. DOI: 10.7759/cureus.60223.

Polysacharide of Agaricus blazei gel mitigates bone necrosis in model of the jaws related to bisphosphonate via Wnt signaling.

Costa de Sousa V, Nunes Sousa F, Felipe Vasconcelos R, Angelino Barreto G, Martins C, Romero Dias N Sci Rep. 2024; 14(1):8215.

PMID: 38589479 PMC: 11002000. DOI: 10.1038/s41598-024-58445-5.

Exosome-targeted delivery of METTL14 regulates NFATc1 m6A methylation levels to correct osteoclast-induced bone resorption.

Yang J, Sun B, Wang Z, Li X, Gao J, Qian J Cell Death Dis. 2023; 14(11):738.

PMID: 37957146 PMC: 10643436. DOI: 10.1038/s41419-023-06263-4.

Influence of antiresorptive/antiangiogenic therapy on the surgical treatment outcomes of experimentally induced peri-implantitis lesions.

Ramanauskaite A, Kruger N, Obreja K, Borchert F, Dahmer I, Schwarz F Clin Oral Investig. 2023; 27(11):6657-6666.

PMID: 37783801 PMC: 10630228. DOI: 10.1007/s00784-023-05275-w.

References

Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

Ata-Ali J, Ata-Ali F, Penarrocha-Oltra D, Galindo-Moreno P . What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res. 2014; 27(2):e38-46. DOI: 10.1111/clr.12526. View

Abtahi J, Agholme F, Aspenberg P . Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. Int J Oral Maxillofac Surg. 2013; 42(5):632-6. DOI: 10.1016/j.ijom.2013.02.007. View

Pautke C, Kreutzer K, Weitz J, Knodler M, Munzel D, Wexel G . Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model. Bone. 2012; 51(3):592-9. DOI: 10.1016/j.bone.2012.04.020. View

Kwon T, Lee C, Park J, Choi S, Rijal G, Shin H . Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2013; 25(5):632-40. DOI: 10.1111/clr.12088. View

Cardemil C, Thomsen P, Wexell C . Jaw Bone Samples From Bisphosphonate-Treated Patients: A Pilot Cohort Study. Clin Implant Dent Relat Res. 2015; 17 Suppl 2:e679-91. DOI: 10.1111/cid.12307. View

Pols H, Felsenberg D, Hanley D, Stepan J, Munoz-Torres M, Wilkin T . Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999; 9(5):461-8. DOI: 10.1007/pl00004171. View

Migliorati C, Woo S, Hewson I, Barasch A, Elting L, Spijkervet F . A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer. 2010; 18(8):1099-106. DOI: 10.1007/s00520-010-0882-1. View

Marino K, Zakhary I, Abdelsayed R, Carter J, ONeill J, Khashaba R . Development of a rat model of bisphosphonate-related osteonecrosis of the jaw (BRONJ). J Oral Implantol. 2011; 38 Spec No:511-8. DOI: 10.1563/AAID-JOI-D-11-00057. View

10.

Harrington J, Ste-Marie L, Brandi M, Civitelli R, Fardellone P, Grauer A . Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2003; 74(2):129-35. DOI: 10.1007/s00223-003-0042-4. View

11.

Li C, Lu W, Seneviratne C, Leung W, Zwahlen R, Zheng L . Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats. Clin Oral Implants Res. 2014; 27(1):1-6. DOI: 10.1111/clr.12502. View

12.

Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop T, Brinzaniuc K . Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell. 2013; 5(1):1. PMC: 3606312. DOI: 10.1186/2045-824X-5-1. View

13.

Akkus O, Polyakova-Akkus A, Adar F, Schaffler M . Aging of microstructural compartments in human compact bone. J Bone Miner Res. 2003; 18(6):1012-9. DOI: 10.1359/jbmr.2003.18.6.1012. View

14.

Vermeer J, Renders G, van Duin M, Jansen I, Bakker L, Kroon S . Bone-site-specific responses to zoledronic acid. Oral Dis. 2016; 23(1):126-133. DOI: 10.1111/odi.12587. View

15.

Verzola M, Frizzera F, de Oliveira G, Pereira R, Rodrigues-Filho U, Nonaka K . Effects of the long-term administration of alendronate on the mechanical properties of the basal bone and on osseointegration. Clin Oral Implants Res. 2014; 26(12):1466-75. DOI: 10.1111/clr.12492. View

16.

Pabst A, Ziebart T, Ackermann M, Konerding M, Walter C . Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig. 2013; 18(3):1015-22. DOI: 10.1007/s00784-013-1060-x. View

17.

Sarkarat F, Motamedi M, Jahanbani J, Sepehri D, Kahali R, Nematollahi Z . Platelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws. Trauma Mon. 2014; 19(2):e17196. PMC: 4080617. DOI: 10.5812/traumamon.17196. View

18.

Rasmusson L, Abtahi J . Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent. 2014; 2014:471035. PMC: 4164242. DOI: 10.1155/2014/471035. View

19.

Roschger P, Fratzl P, ESCHBERGER J, Klaushofer K . Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone. 1998; 23(4):319-26. DOI: 10.1016/s8756-3282(98)00112-4. View

20.

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009; 35(3):119-30. DOI: 10.1111/j.1747-4477.2009.00213.x. View